...
首页> 外文期刊>Biotechnology Progress >Use of a quantitative product-enhanced reverse transcriptase assay tomonitor retrovirus levels in mAb cell-culture and downstream processing
【24h】

Use of a quantitative product-enhanced reverse transcriptase assay tomonitor retrovirus levels in mAb cell-culture and downstream processing

机译:使用定量产物增强逆转录酶测定法监测mAb细胞培养和下游加工中的逆转录病毒水平

获取原文
获取原文并翻译 | 示例

摘要

Murine hybridoma cells used in the production of monoclonal antibodies (mAb's) produce endogenous type C retrovirus particles. Regulatory agencies require a demonstration that mAb's intended for human use are free of retrovirus with an adequate margin of safety. This is usually achieved by validation studies, performed at small scale, to demonstrate that the manufacturing process is capable of removing or inactivating several different model viruses, including a murine retrovirus. In this report, we assess the utility of the TaqMan fluorogenic 5'-nuclease Product-Enhanced Reverse Transcriptase (TM-PERT) assay for measuring reverse transcriptase (RT) activity in cell-culture samples and RT removal by models of processing steps. The levels of RT activity contained in laboratory-scale cell-culture harvests (10(8)-10(13) pU/ mL) were substantially above the detection limit of the TM-PERT assay (similar to 10(6) pU/ mL). The nature of the RT activity from cell culture was complex, but the bulk of RT activity in clarified mAb harvests appears to be contained in large molecular weight viral particles. In laboratory-scale chromatographic runs, sufficient RT activity was present in mAb-containing eluates to accurately calculate its log(10) reduction value (LRV), typically between 2 and 4 log(10) per step. Monoclonal antibody purified using a model purification scheme consisting of three serial columns contained some residual RT activity near the limit of detection. The data indicate that the TM-PERT assay, because it is quantitative and highly sensitive and can be used to analyze a large number of samples in a short period, is ideally suited to investigate and optimize retrovirus clearance in purification processes.
机译:用于生产单克隆抗体(mAb)的鼠杂交瘤细胞可产生内源性C型逆转录病毒颗粒。监管机构要求证明,供人类使用的单克隆抗体不含逆转录病毒,并且具有足够的安全性。这通常通过小规模的验证研究来实现,以证明制造过程能够去除或灭活几种不同的模型病毒,包括鼠逆转录病毒。在本报告中,我们评估了TaqMan荧光5'核酸酶产物增强逆转录酶(TM-PERT)测定法在测量细胞培养样品中逆转录酶(RT)活性以及通过加工步骤模型去除RT的效用。实验室规模的细胞培养物收获物中所含的RT活性水平(10(8)-10(13)pU / mL)大大高于TM-PERT分析的检测极限(类似于10(6)pU / mL )。来自细胞培养的RT活性的性质很复杂,但是澄清的mAb收获物中大部分的RT活性似乎包含在大分子量病毒颗粒中。在实验室规模的色谱运行中,含mAb的洗脱液中存在足够的RT活性,可以准确计算其log(10)降低值(LRV),通常每步2至4 log(10)。使用由三个连续柱组成的模型纯化方案纯化的单克隆抗体在检测极限附近含有一些残留的RT活性。数据表明,TM-PERT测定法定量且高度灵敏,可用于在短时间内分析大量样品,因此非常适合研究和优化纯化过程中的逆转录病毒清除率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号